No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia


    loading  Checking for direct PDF access through Ovid

Abstract

Purpose/BackgroundThis study examined the effect of adjunctive minocycline on body metabolism in risperidone-treated patients with schizophrenia.Methods/ProceduresEach subject had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia and had been on stable dose of risperidone for at least 4 weeks. In a 16-week randomized, double-blind, placebo-controlled study, subjects received either minocycline (200 mg/d) or placebo. Various metabolic parameters, including weight, waist circumference, fasting insulin, glucose, and lipids, were measured at baseline and week 16.Findings/ResultsA total of 63 subjects with schizophrenia were enrolled in the study. Fifty-five patients completed week-16 assessments (27 in the minocycline group, 28 in the placebo group). There were no significant differences between the 2 groups in week 16 changes for body weight, body mass index, waist circumference, fasting insulin, glucose, and lipids (P’s > 0.300).Implications/ConclusionsIn the present study, adjunctive treatment of minocycline did not seem to improve body metabolism in patients with schizophrenia receiving risperidone. The implications for future studies were discussed.

    loading  Loading Related Articles